SPY752.16−0.29%QQQ681.66−0.53%BTC/USD77,755.67+0.54%DIA515.40−0.32%GLD360.39+0.32%TLT81.29+0.22%
BenzingaPremium Services
Premium Services

Market-Moving Exclusives

EXCLUSIVE: Fusion Fuel Expands UAE Footprint, Reaffirms Outlook
EXCLUSIVE: Fusion Fuel Expands UAE Footprint, Reaffirms Outlook
Paul Kedrosky Says AI Bubble May Be Hiding in Private Markets as Anthropic IPO Nears
Paul Kedrosky Says AI Bubble May Be Hiding in Private Markets as Anthropic IPO Nears
EXCLUSIVE: Callan JMB Targets Strong Revenue From New IV Bags Alabama Plant
EXCLUSIVE: Callan JMB Targets Strong Revenue From New IV Bags Alabama Plant
Paul Kedrosky Says AI Bubble May Be Hiding in Private Markets as Anthropic IPO Nears
Paul Kedrosky Says AI Bubble May Be Hiding in Private Markets as Anthropic IPO Nears
EXCLUSIVE: Callan JMB Targets Strong Revenue From New IV Bags Alabama Plant
EXCLUSIVE: Callan JMB Targets Strong Revenue From New IV Bags Alabama Plant
EXCLUSIVE: Exyn Joins DOE-Backed Mining Project to Hunt for Critical Minerals
EXCLUSIVE: Exyn Joins DOE-Backed Mining Project to Hunt for Critical Minerals
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability

Market-Moving Exclusives Recent News

EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
Quantum BioPharma signed an agreement with Thermo Fisher to initiate a Phase 2 clinical trial for its multiple sclerosis therapy, Lucid-MS.
EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
Three U.S. pediatric hospitals added Scienture's hypertension drug Arbli to their formularies, boosting institutional reach.
EXCLUSIVE: Draganfly Secures $10 Million Strategic Capital to Scale Drone Manufacturing
EXCLUSIVE: Draganfly Secures $10 Million Strategic Capital to Scale Drone Manufacturing
Draganfly Inc. raises $10 million through a strategic investment from Unusual Machines and a leading U.S. fund to expand domestic drone production and defense capabilities.
EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies
EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies
Sunshine Biopharma advances its lead coronavirus drug candidate into IND-enabling studies after strong preclinical results in animal models.
EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
GT Biopharma secures FDA IND clearance for GTB-5550, advancing its TriKE therapy into Phase 1 clinical trials for multiple myeloma.
EXCLUSIVE: ZenaTech Expands DaaS Footprint With Merritt Paul Acquisition
EXCLUSIVE: ZenaTech Expands DaaS Footprint With Merritt Paul Acquisition
ZenaTech completed its 29th Drone as a Service acquisition, adding Merritt Paul’s expertise across utility-scale solar, transportation and construction.
EXCLUSIVE: Vivakor To Recognize $270 Million in Q3 Supply & Trading Revenue Amid Crude Oil Demand
EXCLUSIVE: Vivakor To Recognize $270 Million in Q3 Supply & Trading Revenue Amid Crude Oil Demand
Vivakor expects Supply & Trading revenue of around $270 million for Q3 2026, bringing projected nine-month revenue through September to approximately $313.9 million.
EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer
EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer
Sunshine Biopharma outlines K1.1 mRNA pipeline updates, advancing dual oncology therapy to target cold tumors in liver and lung cancer.
EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug
EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug
Sunshine Biopharma secures Canadian regulatory approval for generic Enalapril tablets to treat high blood pressure by 2026.
EXCLUSIVE: Vivakor Targets Critical Minerals Expansion Through Potential M2i Acquisition
EXCLUSIVE: Vivakor Targets Critical Minerals Expansion Through Potential M2i Acquisition
Vivakor M2i Deal talks begin with a 30-day negotiation period focused on commodities, remediation and critical minerals.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved